Filtered By:
Condition: Heart Failure
Drug: Coumadin

This page shows you your search results in order of date. This is page number 19.

Order by Relevance | Date

Total 289 results found since Jan 2013.

Amino Terminal Pro-B-Type Natriuretic Peptide, Secondary Stroke Prevention, and Choice of Antithrombotic Therapy Clinical Sciences
Conclusions— For secondary stroke prevention, elevated NT-proBNP concentrations may identify a subgroup of ischemic stroke patients without known atrial fibrillation, about 5% based on the current study, who may benefit more from anticoagulants than antiplatelet agents. Clinical Trial Registration— This trial was not registered because enrollment began before 2005.
Source: Stroke - February 25, 2013 Category: Neurology Authors: Longstreth, W. T., Kronmal, R. A., Thompson, J. L. P., Christenson, R. H., Levine, S. R., Gross, R., Brey, R. L., Buchsbaum, R., Elkind, M. S. V., Tirschwell, D. L., Seliger, S. L., Mohr, J. P., deFilippi, C. R. Tags: Primary and Secondary Stroke Prevention Clinical Sciences Source Type: research

Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future
Atrial fibrillation (AF) is now said to be at epidemic proportions.1 Although symptoms and heart failure are two of the main reasons that patients with AF suffer from reduced quality of life, thromboembolic complications, particularly stroke, remain the major determinant of significant morbidity and mortality.2 Importantly, the risk of thromboembolism (TE) is completely irrespective of symptoms, and hence the sad fact that people continue to present with catastrophic stroke in AF with no prior history of its detection.3 Appropriate anticoagulation is imperative to reduce the TE/stroke risk. Numerous large scale studies hav...
Source: Heart - February 18, 2013 Category: Cardiology Authors: Rajappan, K. Tags: Drugs: cardiovascular system, Epidemiology Editorials Source Type: research

SMC accepts apixaban (Eliquis®) for prevention of stroke and systemic embolism in adults with AF
Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium has accepted apixaban (Eliquis®) for use within NHS Scotland for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ?75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA class ?II).   The Detailed Advice accompanying the recommendation (see link below) summarises the evidence on efficacy and safety, the clinical effective...
Source: NeLM - Cardiovascular Medicine - February 11, 2013 Category: Cardiology Source Type: news

Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry.
CONCLUSIONS: The Fushimi AF Registry provides a unique snapshot of current AF management in an urban community in Japan. PMID: 23403369 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - February 8, 2013 Category: Cardiology Authors: Akao M, Chun YH, Wada H, Esato M, Hashimoto T, Abe M, Hasegawa K, Tsuji H, Furuke K, On behalf of the Fushimi AF Registry investigators Tags: J Cardiol Source Type: research

National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries
Source: Annals of Pharmacotherapy Area: Evidence > Medicines Management > References Background: Although warfarin therapy reduces stroke incidence in patients with atrial fibrillation (AF), the rate of warfarin use in this population remains low.  In 2008, the US Medicare Part D programme was expanded to pay for medications for Medicare enrollees. Objective: To examine rates and predictors of warfarin use in Medicare Part D beneficiaries with AF. Methods: This population-based retrospective cohort study used claims data from 41,447 Medicare beneficiaries aged 66 and older with at least 2 AF diagnoses in ...
Source: NeLM - Cardiovascular Medicine - January 24, 2013 Category: Cardiology Source Type: news

National Heart Foundation of Australia consensus statement on catheter ablation as a therapy for atrial fibrillation.
Abstract Atrial fibrillation (AF) is estimated to affect 1%-2% of the population. It is increasing in prevalence and is associated with excess mortality, considerable morbidity and hospitalisations. AF is responsible for a significant and growing societal financial burden. Catheter ablation is an increasingly used therapeutic strategy for the management of AF; however, some confusion exists among those caring for patients with this condition about the role and optimal use of ablative treatments for AF. Our aim in this consensus statement is to provide recommendations on the use of primary catheter ablation for AF ...
Source: Med J Aust - January 21, 2013 Category: Journals (General) Authors: Kalman JM, Sanders P, Brieger DB, Aggarwal A, Zwar NA, Tatoulis J, Tay AE, Wilson A, Branagan MG Tags: Med J Aust Source Type: research

Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations
Source: European Journal of Clinical Pharmacology Area: Evidence > Medicines Management > References Background: Little is known about prescription trends in atrial fibrillation (AF) in primary health care in Sweden. Objective: The aim was to study time trends in pharmacotherapy, in men and women with AF.  We also aimed at studying doctors' adherence to CHADS2 for prescribing warfarin.  CHADS2 assesses stroke risk by presence of known risk factors, i.e. congestive heart failure, hypertension, age over 75 years, diabetes, previous stroke and transient ischaemic attack. Methods: Data were obtained from...
Source: NeLM - Cardiovascular Medicine - January 18, 2013 Category: Cardiology Source Type: news

Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients with Atrial Fibrillation: 2.3 Year Follow-Up of the PROTECT AF Trial.
CONCLUSIONS: The "local" strategy of LAA closure is noninferior to "systemic" anticoagulation with Warfarin. PROTECT AF has, for the first time, implicated the LAA in the pathogenesis of stroke in AF. CLINICAL TRIAL REGISTRATION INFORMATION: Clinicaltrials.gov; Unique Identifier: NCT00129545. PMID: 23325525 [PubMed - as supplied by publisher]
Source: Circulation - January 16, 2013 Category: Cardiology Authors: Reddy VY, Doshi SK, Siever H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D Tags: Circulation Source Type: research

National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of medicare part d beneficiaries.
CONCLUSIONS: Warfarin use rates vary by patient characteristics and region, with higher rates among residents of the Midwest and among patients seen by cardiologists and PCPs. Preventing stroke-related disability in AF requires implementation of evidence-based initiatives to increase warfarin use. PMID: 23324508 [PubMed - in process]
Source: The Annals of Pharmacotherapy - January 1, 2013 Category: Drugs & Pharmacology Authors: Raji MA, Lowery M, Lin YL, Kuo YF, Baillargeon J, Goodwin JS Tags: Ann Pharmacother Source Type: research

Role of new drugs for management of atrial fibrillation.
CONCLUSIONS: Use of dronedarone should be limited to patients with paroxysmal or persistent AF and should not be used in patients with heart failure or with permanent AF. Newer antithrombotic agents appear to be promising alternatives for the prevention of stroke in patients with AF; however, more data are needed to understand their role. PMID: 23249869 [PubMed - in process]
Source: The Annals of Pharmacotherapy - December 1, 2012 Category: Drugs & Pharmacology Authors: Hollands JM, Gowan M, Riney JN, Deal EN, Kates AM Tags: Ann Pharmacother Source Type: research

Warfarin versus Aspirin for Prevention of Stroke in Heart Failure: A Meta-analysis of Randomized Controlled Clinical Trials
Conclusions: Compared with aspirin, warfarin reduced the risk of stroke while conferring an increased risk of major hemorrhage. Warfarin does not increase mortality or confer an increased risk of ICH compared with aspirin.
Source: Journal of Stroke and Cerebrovascular Diseases - November 21, 2012 Category: Neurology Authors: Gyanendra Kumar, Munish Kumar Goyal Tags: Original Articles Source Type: research

The impact of CHADS2 score on late stroke after the Cox maze procedure
Conclusions: The risk of stroke or transient ischemic attack in patients after a surgical Cox maze procedure was low and not associated with CHADS2 score or warfarin use. Given the known risks of warfarin, we recommend discontinuation of anticoagulation 3 months after the procedure if the patient has no evidence of atrial fibrillation, has discontinued antiarrhythmic medications, and is without any other indication for systemic anticoagulation.
Source: The Journal of Thoracic and Cardiovascular Surgery - July 23, 2012 Category: Cardiovascular & Thoracic Surgery Authors: Mitchell Pet, Jason O. Robertson, Marci Bailey, Tracey J. Guthrie, Marc R. Moon, Jennifer S. Lawton, Andrew Rinne, Ralph J. Damiano, Hersh S. Maniar Tags: Acquired Cardiovascular Disease Source Type: research

Warfarin may reduce risk of ischemic stroke by preventing atrial fibrillation for patients with heart failure and sinus rhythm
As compared with the general population, patients with reduced ejection fraction who are in sinus rhythm are observed with a higher risk for ischemic stroke. This relationship is caused by left ventricular stasis, a systemic hypercoagulable state, and endocardial dysfunction in a situation of impaired left ventricular systolic function . Therefore, the issue whether antithrombotic agents especially aspirin or warfarin could successfully prevent stroke for patients with heart failure and sinus rhythm has been tested in a series of clinical trials. The former two trials (the Warfarin/Aspirin Study in Heart Failure (WASH) tri...
Source: International Journal of Cardiology - July 16, 2012 Category: Cardiology Authors: Gen-Min Lin, Yi-Hwei Li, Lamin .E.S. Jaiteh, Chih-Lu Han Tags: Letters to the Editor Source Type: research

A001 * Barriers of warfarin use for atrial fibrillation patients in Hong Kong
Conclusion: Hong Kong physiciansâ™ knowledge level of stroke prevention management was on average lower than Australian family physiciansâ™, and Hong Kong patientsâ™ knowledge of AF and warfarin therapy was in general poor, and poorer than that of UK and Finland patients, and US patients respectively. Interventions should be done to improve both physiciansâ™ and patientsâ™ knowledge in order to better utilize warfarin for AF patients.
Source: European Journal of Heart Failure Supplements - February 23, 2012 Category: Cardiology Authors: Lee, W. Y., Tam, C. S., Yan, P. Y., Lam, Y. Y., Duchatelet, S., Peat, R. A., Denjoy, I., Itoh, H., Berthet, M., Crotti, L., Ohno, S., Pedrazzini, M., Klug, D., Schwartz, P. J., Shimizu, W., Horie, M., Tregouet, D. A., Guicheney, P., Tiong, W. N., Hwang, S Tags: Arrhythmia Source Type: research

Identifying a High Stroke Risk Subgroup in Individuals with Heart Failure
Conclusions: The combination of previous stroke/TIA and DM increases the incidence of stroke in participants with HF without AF. No analyzed subgroup had a stroke rate high enough to make it likely that the benefits of warfarin would outweigh the risks.
Source: Journal of Stroke and Cerebrovascular Diseases - December 6, 2011 Category: Neurology Authors: Patrick M. Pullicino, Leslie A. McClure, Virginia J. Howard, Virginia G. Wadley, Monika M. Safford, James F. Meschia, Aaron Anderson, George Howard, Elsayed Z. Soliman Tags: Original Articles Source Type: research